Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)
- Funder
- National Institutes of Health
- Award amount
- Not specified
- Deadline
- February 17, 2028
- Eligible countries
- United States
Summary
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for exploratory and early-stage projects that focus on undruggable target classes within intractable human disease. Applicants will identify a human disease relevant undruggable target class and develop a method or agent that is selective for one or more targets within that target class. This NOFO is intended to jumpstart research that demonstrates innovative strategies to modulate targets that cannot be addressed by established therapeutic types, furthering the development of methods and/or agents selective for undruggable target classes.
Summary as listed on Grants.gov (opportunity 359154). Always read the full announcement for eligibility, limits and how to apply.
Read the full announcement on Grants.gov →What National Institutes of Health reviewers look for
- Importance of the research (significance and innovation), scored 1–9.
- Rigor and feasibility of the approach, scored 1–9. Preliminary data and alternative strategies carry much of this.
- Expertise and resources, rated sufficient or not, without a score.
- Overall impact: the likelihood the project will have a sustained, powerful influence on its field.
Read our guide: what funded applications do →
See how this call matches your research
Build a free research profile and GrantMatch scores every open call against your work, tracks your deadlines and reminds you before they pass.
Get matched free